Introduction of SARS-COV-2 C.37 (WHO VOI lambda) from Peru to Italy
- PMID: 34314049
- PMCID: PMC8427114
- DOI: 10.1002/jmv.27235
Introduction of SARS-COV-2 C.37 (WHO VOI lambda) from Peru to Italy
Conflict of interest statement
The authors declare that there are no conflicts of interest.
References
-
- Tracking SARS‐CoV‐2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
-
- Tada T, Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR. SARS‐CoV‐2 lambda variant remains susceptible to neutralization by mRNA vaccine‐elicited antibodies and convalescent serum. bioRxiv. Published online July 03, 2021. 10.1101/2021.07.02.450959 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
